目的 观察血塞通注射液联合替格瑞洛片治疗脑梗死的临床疗效。方法 选取2022年1月—2024年4月于西宁市第二人民医院接受治疗的共计116例脑梗死患者作为研究对象。采用随机数字表法将患者分为对照组和治疗组，每组58例。对照组饭后口服替格瑞洛片，首次服用180 mg，此后每次90 mg，2次/d。治疗组在对照组的基础上静滴血塞通注射液200～400 mg，以5%～10%葡萄糖注射液250～500 mL稀释，1次/d。两组患者连续治疗15 d。比较两组临床疗效、脑神经功能、日常生活活动能力、脑氧代谢指标。结果 与对照组相比，治疗组的总有效率（93.10%）大于对照组的总有效率（74.14%），差异具有统计学意义（P＜0.05）。治疗后，两组美国国立卫生研究院卒中量表（NIHSS）评分明显降低，Barthel指数明显升高（P＜0.05），且治疗组NIHSS评分低于对照组，Barthel指数高于对照组（P＜0.05）。经过治疗后，两组的动脉血氧含量、动静脉血氧含量差、脑氧摄取率均显著降低（P＜0.05），治疗组的动脉血氧含量、动静脉血氧含量差、脑氧摄取率低于对照组（P＜0.05）。结论 血塞通注射液联合替格瑞洛片可显著提高临床疗效，促进神经功能恢复，提升患者日常生活自理能力，改善脑氧代谢指标。

Objective To observe the efficacy of Xuesaitong Injection combined with Ticagrelor Tablets in treatment of cerebral infarction. Methods A total of 116 patients with cerebral infarction who received treatment at Xining Second People's Hospital from January 2022 to April 2024 were selected as the research subjects. The patients were divided into control group and treatment group using a random number table method, with 58 cases in each group. The control group took Ticagrelor Tablets orally after meals, taking 180 mg for the first time and 90 mg each time thereafter, twice daily. The treatment group received iv infusion of 200 — 400 mg Xuesaitong Injection on the basis of the control group, diluted with 5%— 10% glucose injection 250 — 500 mL, once daily. Two groups of patients were treated continuously for 15 d. The clinical efficacy, brain nerve function, daily living activity ability, and cerebral oxygen metabolism indicators were compared between two groups. Results Compared with the control group, the total effective rate of the treatment group (93.10%) was higher than that of the control group (74.14%), and the difference was statistically significant (P < 0.05). After treatment, the NIHSS scores of two groups decreased significantly, while the Barthel index increased significantly (P < 0.05), and the NIHSS score of the treatment group was lower than that of the control group, while the Barthel index was higher than that of the control group (P < 0.05). After treatment, the arterial oxygen content, arteriovenous oxygen content difference, and cerebral oxygen extraction rate of two groups were significantly reduced (P < 0.05). The arterial oxygen content, arteriovenous oxygen content difference, and cerebral oxygen extraction rate of the treatment group were lower than those of the control group (P < 0.05). Conclusion The combination of Xuesaitong Injection and Ticagrelor Tablets can significantly improve clinical efficacy, promote neurological function recovery, enhance patients' daily self-care ability, and improve cerebral oxygen metabolism indicators.

R971

青海省科技计划项目（2020-ZJ-754）